Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing

Yong Shen, Rick Li, Kristian Teichert, Kara E. Montbleau, Jeffrey M. Verboon, Richard A. Voit, Vijay G. Sankaran*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Increased production of fetal hemoglobin (HbF) can ameliorate the severity of sickle cell disease and β-thalassemia. BCL11A has been identified as a key regulator of HbF silencing, although its precise mechanisms of action remain incompletely understood. Recent studies have identified pathogenic mutations that cause heterozygous loss-of-function of BCL11A and result in a distinct neurodevelopmental disorder that is characterized by persistent HbF expression. While the majority of cases have deletions or null mutations causing haploinsufficiency of BCL11A, several missense variants have also been identified. Here, we perform functional studies on these variants to uncover specific liabilities for BCL11A’s function in HbF silencing. We find several mutations in an N-terminal C2HC zinc finger that increase proteasomal degradation of BCL11A. We also identify a distinct C-terminal missense variant in the fifth zinc finger domain that we demonstrate causes loss-of-function through disruption of DNA binding. Our analysis of missense variants causing loss-of-function in vivo illuminates mechanisms by which BCL11A silences HbF and also suggests potential therapeutic avenues for HbF induction to treat sickle cell disease and β-thalassemia.

Original languageEnglish
Article numbere1009835
JournalPLoS Genetics
Volume17
Issue number10
DOIs
Publication statusPublished - 11 Oct 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing'. Together they form a unique fingerprint.

Cite this